

<b>CLINICAL LEADERSHIP EXECUTIVE OUTBRIEF</b>	
Date of meeting	27th April 2021
Attendees	Group Triumvirates (Group Directors, Group Directors of Nursing and Group Directors of Operations), Director of Therapies and Executive Directors.
Apologies	Toby Lewis, Sarah Yusuf, Niten Makwana, Helen Hurst, Marion Pavitt, Shinade Coughlan, Demetri Wade
Key points of discussion relevant to the Board	<ul style="list-style-type: none"> <li>• Received the draft 2021/22 Capital Clinical Equipment programme and agreed that the programme would be scrutinised by the clinical groups for a final version to be approved next month.</li> <li>• Received a paper from the CFO about the size and scale of the investment and cost pressure prioritisation process for 2021/22. Noted that revenue balance can be achieved but Covid costs must reduce, CIP run rate must be delivered and a running total of £17m worth of new investments must be reduced.</li> <li>• Planned Care and Recovery – COO assured CLE that robust plans for priority 1 and priority 2 electives would deliver a summer 2021/2022 recovery however without significant increases in baseline capacity P4 elective recovery would take us beyond the end of the financial year.</li> <li>• Logistics strategy was approved in principle and CLE awaits the production of the final business case for the unification of all trust logistics.</li> </ul>
Positive highlights of note	<ul style="list-style-type: none"> <li>• Clear two point strategy for improving mortality rates was received and approved</li> </ul>
Matters of concern or key risks to escalate to the Board	<ul style="list-style-type: none"> <li>• Nil</li> </ul>
Matters presented for information or noting	<ul style="list-style-type: none"> <li>• IQPR</li> <li>• Finance Report: Month 12</li> </ul>
Decisions made	<ul style="list-style-type: none"> <li>• As per above</li> </ul>

**Richard Beeken, Interim Chief Executive  
 Chair, Clinical Leadership Executive**

***For the meeting of the Trust Board scheduled for 6th May 2021***